Comparative Pharmacology
Head-to-head clinical analysis: SULFATRIM versus TRIPLE SULFOID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SULFATRIM versus TRIPLE SULFOID.
SULFATRIM vs TRIPLE SULFOID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfatrim is a combination of sulfamethoxazole, a dihydropteroate synthase inhibitor that blocks folate synthesis, and trimethoprim, a dihydrofolate reductase inhibitor that blocks reduction of dihydrofolate to tetrahydrofolate, resulting in sequential inhibition of bacterial folate metabolism.
Triple sulfoid (sulfadiazine, sulfamethazine, sulfamerazine) competes with para-aminobenzoic acid (PABA) to inhibit dihydropteroate synthase, blocking bacterial folate synthesis.
160 mg trimethoprim / 800 mg sulfamethoxazole (1 DS tablet) orally every 12 hours for 10-14 days.
2 tablets orally every 6 hours for 10-14 days; each tablet contains sulfadiazine 270 mg, sulfamerazine 270 mg, and sulfamethazine 270 mg.
None Documented
None Documented
Sulfamethoxazole: 9-11 hours (prolonged in renal impairment, e.g., up to 30 hours in severe renal failure). Trimethoprim: 8-10 hours (prolonged in hepatic impairment).
10-12 hours in normal renal function; prolonged to 24-48 hours in severe renal impairment (CrCl <30 mL/min)
Renal (70-80% as unchanged sulfamethoxazole and N4-acetylated metabolite; 30-40% as unchanged trimethoprim), biliary/fecal (20-30% sulfamethoxazole; 10-20% trimethoprim)
Renal: ~70% as unchanged drug; hepatic metabolism: ~20%; fecal: ~10%
Category C
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic